1038261-86-7 Usage
Chemical structure
A chemical compound with a triazole ring and a carboxylic acid functional group, featuring a 3,4-difluorophenyl substituent attached to the triazole ring.
Potential applications
Medicinal chemistry, specifically as a building block for the synthesis of biologically active molecules.
Biological activities
Triazole derivatives have been studied for their antimicrobial, anticancer, and antiviral properties.
Chemical modification
The carboxylic acid functionality in 1-(3,4-difluorophenyl)-1H-1,2,3-triazole-4-carboxylic acid provides opportunities for further chemical modification.
Structure-activity relationship studies
The carboxylic acid group allows for the evaluation of the compound's structure-activity relationship, which is crucial for optimizing its biological activity.
Pharmaceutical development
The synthesis, characterization, and evaluation of 1-(3,4-difluorophenyl)-1H-1,2,3-triazole-4-carboxylic acid and its derivatives could lead to the development of new pharmaceuticals with improved therapeutic properties.
Check Digit Verification of cas no
The CAS Registry Mumber 1038261-86-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,8,2,6 and 1 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1038261-86:
(9*1)+(8*0)+(7*3)+(6*8)+(5*2)+(4*6)+(3*1)+(2*8)+(1*6)=137
137 % 10 = 7
So 1038261-86-7 is a valid CAS Registry Number.
1038261-86-7Relevant academic research and scientific papers
Liu, Mingmei,Hou, Yunlei,Yin, Weile,Zhou, Shunguang,Qian, Ping,Guo, Zhuang,Xu, Liying,Zhao, Yangfang
, p. 96 - 108 (2016)
A series of 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety were designed, synthesized and evaluated for their in vitro cytotoxic activities against four typical cancer cell lines (A549, H460, HT-29, and MKN-45). Most compounds showed moderate-to-excellent antiproliferative activity. Compounds 32, 36, 37, 45, 51, and 52 were further examined for their inhibitory activity against c-Met kinase. The promising compound 37, with a c-Met IC50 value of 2.27 nM, was identified as a multitargeted receptor tyrosine kinase inhibitor. The analysis of their structure-activity relationships indicated that compounds with EWGs, especially chloro group, at 2-position on the phenyl ring (moiety B) have potent antitumor activity.
